Dcf1 deficiency induces hypomyelination by activating Wnt signaling

Area of Science:

• Neuroscience
• Cell Biology
• Developmental Biology

Background:

• Myelination is vital for neural function, and hypomyelination underlies various neurological disorders.
• The molecular mechanisms driving hypomyelination remain largely unknown.
• Understanding these mechanisms is key to developing therapeutic strategies for neurological diseases.

Purpose of the Study:

• To investigate the role of dendritic cell factor 1 (Dcf1) in myelination.
• To elucidate the impact of Dcf1 deficiency on neurological function and myelin integrity.
• To explore the underlying molecular pathways affected by Dcf1 dysfunction.

Main Methods:

• In vitro and in vivo models were utilized to study Dcf1's function.
• Dcf1-null mice were analyzed for myelin-associated protein levels (MBP, MAG, CNPase) and myelin sheath thickness via electron microscopy.
• Motor coordination and balance were assessed in Dcf1-null mice.
• Gain-of-function studies using in utero electroporation were performed.
• Comparison with cuprizone-induced demyelination models was conducted.
• Wnt/β-catenin signaling pathway activity was investigated.

Main Results:

• Dcf1 is essential for normal myelination, motor coordination, and balance.
• Dcf1 deficiency resulted in downregulated myelin-associated proteins and thinner myelin sheaths.
• Dcf1-null mice exhibited impaired neurological function, confirmed by motor and balance tests.
• Re-expression of Dcf1 rescued hypomyelination in Dcf1-null mouse brains.
• Dcf1 knockout mice showed a phenotype similar to cuprizone-induced demyelination.
• Insufficient Dcf1 led to hyperactivation of the Wnt/β-catenin signaling pathway.

Conclusions:

• Dcf1 plays a critical role in maintaining normal myelination and neurological function.
• Dcf1 deficiency causes hypomyelination through downregulation of key myelin proteins and Wnt/β-catenin pathway dysregulation.
• This study enhances the understanding of hypomyelination pathogenesis and identifies Dcf1 as a potential therapeutic target.